Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jefferey Bloom

Sports Medicine Costa Mesa, CA Doctor of Osteopathy

NPI 1669472148 CMS profile 256641

3140 Red Hill Ave, Ste 120, Costa Mesa, CA 92626

Open in the dashboard

General payments

$3,889

168 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jefferey Bloom of Costa Mesa, CA is reported in the CMS Open Payments database as having received $3,889 across 168 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $265 11
2024 General $394 21
2023 General $603 18
2022 General $682 28
2021 General $881 44
2020 General $541 28
2019 General $524 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jefferey Bloom
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Jefferey Bloom were reported at $265. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Jefferey Bloom Sports Medicine median Middle half National median
2019 $524 $119 $35–$362 $163
2020 $541 $77 $24–$275 $114
2021 $881 $104 $28–$340 $132
2022 $682 $94 $31–$272 $149
2023 $603 $91 $34–$271 $160
2024 $394 $126 $38–$294 $164
2025 $265 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $748 37 payments
  2. Lilly USA, LLC $627 28 payments
  3. Gilead Sciences, Inc. $426 18 payments
  4. Allergan Inc. $410 19 payments
  5. Novo Nordisk Inc $220 11 payments
  6. Kowa Pharmaceuticals America, Inc. $155 8 payments
  7. Merck Sharp & Dohme Corporation $127 7 payments
  8. Horizon Therapeutics plc $125 1 payment
  9. Smith+Nephew, Inc. $125 1 payment
  10. Genentech, Inc. $111 1 payment
  11. Other $815 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,889 168 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $647 31 payments
  2. MOUNJARO $428 19 payments
  3. VRAYLAR Neuroscience $340 15 payments
  4. Ozempic $182 9 payments
  5. TRULICITY $179 9 payments
  6. ZEPBOUND $167 10 payments
  7. Livalo $155 8 payments
  8. RYBELSUS $148 8 payments
  9. JANUVIA $127 7 payments
  10. TEPEZZA $125 1 payment
  11. Other $2,009 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 64 drugs

Part D claims

1,805

Median for Family Practice: 1,826

Drug cost

$141,826

Median for Family Practice: $120,094

Branded share of claims

17.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 32 $42,424
Jardiance Empagliflozin Brand 30 $27,636
Januvia Sitagliptin Phosphate Brand 23 $16,839
Eliquis Apixaban Brand 12 $15,949
Praluent Pen Alirocumab Brand 12 $5,697
Humalog Kwikpen U-200 Insulin Lispro Brand 13 $5,426
Tresiba Flextouch U-200 Insulin Degludec Brand 11 $2,538
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 14 $2,153
Celecoxib Generic 29 $1,655
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 28 $1,407

The 10 drugs with the highest cost, of 64 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$61,941

Of which drugs: $559

Medicare patients

127

Average age 75

Services billed

1,297

60 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 42%
Arthritis 41%
Ischemic heart disease 37%
Chronic kidney disease 20%
Depression 17%
Atrial fibrillation 14%
COPD 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 18 19 $407

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $117
$117 — —
ZEPBOUND
  • Lilly USA, LLC $71
$71 — —
VRAYLAR
  • AbbVie, Inc. $27
$27 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $25
$25 — —
TERIPARATIDE
  • Alvogen Inc $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record